T-DXd for HER2-positive breast cancer that has spread to the brain
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests how well an imaging test can predict the effectiveness of the drug T-DXd in people with HER2-positive breast cancer that has spread to the brain. It aims to see if a special scan can help guide treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You are able to take care of yourself (ECOG score 0-2).
- You have HER2-positive breast cancer that cannot be surgically removed or has spread, and it is confirmed by a lab test.
- You have at least one brain tumor that measures at least 1 cm and has not been treated with radiation.
- You are planning to start treatment with T-DXd.
- You have adequate bone marrow, liver, kidney, and heart function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how well the drug trastuzumab deruxtecan (Enhertu) works for women and men with HER2-positive breast cancer that has spread to the brain. Researchers want to see how much of the drug gets into the spinal fluid and if it helps shrink brain tumors.
This trial tests a new way of giving the targeted drug T-DXd—directly into the fluid around your spine (intrathecal) or through a device under your scalp called an Ommaya reservoir. It's designed for people with HER2-positive breast cancer that has spread to the brain or the lining of the brain/spinal cord.
This trial tests a combination of a targeted drug (T-DXd) and precise radiation (stereotactic radiotherapy) for people with HER2-positive breast cancer that has spread to the brain. The goal is to see if this approach can better control brain tumors.
This trial tests a new combination of a targeted drug (T-DXd) with brain radiation for women with breast cancer that has spread to the brain and is HER2-positive or HER2-low. The goal is to see if this approach is safe and works better than radiation alone.
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
This study tests how well trastuzumab deruxtecan (T-DXd) works for people with HER2-low breast cancer that has spread. The treatment is given as part of routine care, and the trial uses advanced imaging (PET/CT) to measure response.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.